Skip to main content
Journal cover image

Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia.

Publication ,  Journal Article
Resnick, SG; Rosenheck, RA; Canive, JM; De Souza, C; Stroup, TS; McEvoy, J; Davis, S; Keefe, RSE; Swartz, M; Lieberman, J
Published in: J Behav Health Serv Res
April 2008

Employment has been increasingly recognized as an important goal for individuals with schizophrenia. Previous research has shown mixed results on the relationship of specific antipsychotic medications to employment outcomes, with some studies finding greater benefits for second-generation antipsychotic medications (SGAs) over first-generation antipsychotic medication (FGAs). A randomized controlled trial (CATIE) examined medication assignment and both employment outcomes and participation in psychosocial rehabilitation (PSR) among 1,121 individuals with a diagnosis of schizophrenia randomized to SGAs (olanzapine, quetiapine, risperidone, ziprasidone) or one FGA (perphenazine). Service use and employment were assessed at quarterly interviews. There were no differences between medication groups on employment outcomes or participation in PSR. Consistent with other CATIE results, there were no differences in employment or participation in PSR among these five medications, including the FGA perphenazine.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Behav Health Serv Res

DOI

EISSN

1556-3308

Publication Date

April 2008

Volume

35

Issue

2

Start / End Page

215 / 225

Location

United States

Related Subject Headings

  • Schizophrenia
  • Psychiatry
  • Perphenazine
  • Outcome Assessment, Health Care
  • Middle Aged
  • Male
  • Interviews as Topic
  • Humans
  • Female
  • Employment
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Resnick, S. G., Rosenheck, R. A., Canive, J. M., De Souza, C., Stroup, T. S., McEvoy, J., … Lieberman, J. (2008). Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. J Behav Health Serv Res, 35(2), 215–225. https://doi.org/10.1007/s11414-007-9101-3
Resnick, Sandra G., Robert A. Rosenheck, Jose M. Canive, Cyril De Souza, T Scott Stroup, Joseph McEvoy, Sonia Davis, Richard S. E. Keefe, Marvin Swartz, and Jeffrey Lieberman. “Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia.J Behav Health Serv Res 35, no. 2 (April 2008): 215–25. https://doi.org/10.1007/s11414-007-9101-3.
Resnick SG, Rosenheck RA, Canive JM, De Souza C, Stroup TS, McEvoy J, et al. Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. J Behav Health Serv Res. 2008 Apr;35(2):215–25.
Resnick, Sandra G., et al. “Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia.J Behav Health Serv Res, vol. 35, no. 2, Apr. 2008, pp. 215–25. Pubmed, doi:10.1007/s11414-007-9101-3.
Resnick SG, Rosenheck RA, Canive JM, De Souza C, Stroup TS, McEvoy J, Davis S, Keefe RSE, Swartz M, Lieberman J. Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. J Behav Health Serv Res. 2008 Apr;35(2):215–225.
Journal cover image

Published In

J Behav Health Serv Res

DOI

EISSN

1556-3308

Publication Date

April 2008

Volume

35

Issue

2

Start / End Page

215 / 225

Location

United States

Related Subject Headings

  • Schizophrenia
  • Psychiatry
  • Perphenazine
  • Outcome Assessment, Health Care
  • Middle Aged
  • Male
  • Interviews as Topic
  • Humans
  • Female
  • Employment